Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4.

JCI Insight · 2025 · PMC11981626 · PMID 40014402

Europe PMC DOI

hedged sentence

0.0643

closest p · 1.3× alpha

0.0643

boldest claim

The sentences

a nonsignificant trendP = 0.0643so close (0.05 < p ≤ 0.1)

1 and 5) from CPI-treated mice and a nonsignificant trend ( P = 0.0643) in CD4 + Tregs (cl. 3) ( Figure 2I ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.